全文获取类型
收费全文 | 25199篇 |
免费 | 2337篇 |
国内免费 | 78篇 |
专业分类
耳鼻咽喉 | 260篇 |
儿科学 | 593篇 |
妇产科学 | 344篇 |
基础医学 | 3068篇 |
口腔科学 | 804篇 |
临床医学 | 3269篇 |
内科学 | 5398篇 |
皮肤病学 | 614篇 |
神经病学 | 1857篇 |
特种医学 | 1029篇 |
外科学 | 3540篇 |
综合类 | 469篇 |
一般理论 | 24篇 |
预防医学 | 2670篇 |
眼科学 | 352篇 |
药学 | 2008篇 |
中国医学 | 23篇 |
肿瘤学 | 1292篇 |
出版年
2021年 | 359篇 |
2020年 | 206篇 |
2019年 | 346篇 |
2018年 | 377篇 |
2017年 | 278篇 |
2016年 | 333篇 |
2015年 | 384篇 |
2014年 | 528篇 |
2013年 | 833篇 |
2012年 | 1133篇 |
2011年 | 1118篇 |
2010年 | 633篇 |
2009年 | 581篇 |
2008年 | 1034篇 |
2007年 | 1042篇 |
2006年 | 1085篇 |
2005年 | 1098篇 |
2004年 | 1022篇 |
2003年 | 982篇 |
2002年 | 970篇 |
2001年 | 978篇 |
2000年 | 1008篇 |
1999年 | 855篇 |
1998年 | 326篇 |
1997年 | 270篇 |
1996年 | 256篇 |
1995年 | 266篇 |
1994年 | 216篇 |
1993年 | 218篇 |
1992年 | 612篇 |
1991年 | 630篇 |
1990年 | 589篇 |
1989年 | 523篇 |
1988年 | 489篇 |
1987年 | 485篇 |
1986年 | 482篇 |
1985年 | 475篇 |
1984年 | 343篇 |
1983年 | 297篇 |
1982年 | 220篇 |
1981年 | 209篇 |
1979年 | 327篇 |
1978年 | 238篇 |
1977年 | 204篇 |
1975年 | 166篇 |
1974年 | 214篇 |
1973年 | 204篇 |
1972年 | 169篇 |
1971年 | 192篇 |
1970年 | 170篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
11.
12.
13.
Phase I study of high-dose cytosine arabinoside and etoposide in patients with advanced malignancies
Bayard L. Powell Hyman B. Muss Robert L. Capizzi Mary E. Caponera Douglas R. White Patricia J. Zekan James N. Atkins Don V. Jackson Jr. Frederick Richards II John B. Craig Julia M. Cruz Charles L. Spurr 《Cancer chemotherapy and pharmacology》1987,19(3):250-252
Summary Cytosine arabinsodie (ara-C) and etoposide (VP-16) display synergy in the laboratory. Twenty-six patients participated in a phase I study of high-dose ara-C in combination with VP-16. The dose of VP-16 was held constant at 50 mg/m2 as an intermittent infusion over 33 h; escalating doses of ara-C were given as infusions during hours 9–12 and 21–24. Myelosuppression was the dose-limiting toxicity and occurred with doses considerably less than those expected from studies of the two drugs as single agents. The suggested initial doses for phase II trials with this schedule are 750 mg/m2×2 doses of ara-C and 50 mg/m2 of VP-16. Nonhematologic toxicity was minimal; therefore, further dose escalation is feasible in patients in whom myelosuppression is acceptable.Supported in part by grants from the National Cancer Institute (CA-12197 and CA-09422) and the American Cancer Society CF-85-182 相似文献
14.
15.
Usher syndrome: clinical findings and gene localization studies 总被引:3,自引:0,他引:3
William J. Kimberling Sandra L. H. Davenport Ira Priluck Valorie White Karen Biscone-Halterman Patrick E. Brookhouser Claes G. Mller Gunnar Lund Timothy J. Grissom Michael D. Weston 《The Laryngoscope》1989,99(1):66-72
The issue of genetic heterogeneity is a critical problem in the localization of the gene(s) for Usher syndrome. Based on the data obtained on families studied to date, the differences between type I and type II Usher syndrome appear quite distinct with regard to auditory and vestibular function. Although the majority of families can be confidently diagnosed as typical type I or type II, clinical investigations revealed four families with findings that did not fit into either of the two more common subtypes. These findings emphasize the critical importance of an in-depth clinical analysis concomitant with the linkage investigation to assure accurate subtyping of Usher syndrome. Based on an analysis of only those families with definite type I or type II Usher syndrome, approximately 17% of the genome can be excluded as a potential site of the gene for type I, and 14% can be excluded as the site for the type II gene. This study will continue until the Usher gene(s) is successfully localized. 相似文献
16.
17.
18.
19.
20.
M. S. Reddy S. A. White B. C. Jaques N. Torpey D. M. Manas 《American journal of transplantation》2007,7(10):2422-2424
As demand for donor pancreases increases, attempts are being made to utilize even marginal grafts for transplantation. Injury during pancreas recovery can predispose to posttransplant complications and graft loss. Early recognition and correction can salvage these grafts. The authors report an instance of poor segmental perfusion of the pancreas graft that was salvaged by pancreas head resection and enteric drainage through a Roux-en-Y pancreatico-jejunostomy. 相似文献